Dynavax Technologies Co. (NASDAQ:DVAX) to Post Q3 2022 Earnings of $0.23 Per Share, William Blair Forecasts – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) – Equities research analysts at William Blair cut their Q3 2022 earnings estimates for shares of Dynavax Technologies in a research report issued to clients and investors on Friday, August 5th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $0.23 for the quarter, down from their prior forecast of $0.29. The consensus estimate for Dynavax Technologies’ current full-year earnings is $1.15 per share. William Blair also issued estimates for Dynavax Technologies’ Q4 2022 earnings at $0.36 EPS.
Separately, StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Friday. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $28.00.
Dynavax Technologies Stock Performance
Shares of Dynavax Technologies stock opened at $16.65 on Monday. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.02 and a quick ratio of 1.85. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of 11.89 and a beta of 1.30. The business has a 50-day moving average of $13.11 and a 200 day moving average of $11.76. Dynavax Technologies has a 12 month low of $7.26 and a 12 month high of $21.39.
Dynavax Technologies (NASDAQ:DVAX – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.02). Dynavax Technologies had a return on equity of 139.14% and a net margin of 34.58%. The company had revenue of $113.99 million for the quarter, compared to analyst estimates of $117.76 million. During the same period in the prior year, the business posted $0.01 earnings per share.
Hedge Funds Weigh In On Dynavax Technologies
A number of hedge funds have recently modified their holdings of the business. Advisors Asset Management Inc. increased its position in shares of Dynavax Technologies by 498.0% during the first quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,967 shares during the last quarter. Quantbot Technologies LP grew its position in Dynavax Technologies by 940.7% during the first quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 2,267 shares in the last quarter. Banque Cantonale Vaudoise purchased a new position in Dynavax Technologies during the second quarter worth about $67,000. Signaturefd LLC lifted its stake in Dynavax Technologies by 12,690.7% during the first quarter. Signaturefd LLC now owns 5,500 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 5,457 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Dynavax Technologies in the 1st quarter valued at about $102,000. Institutional investors and hedge funds own 76.80% of the company’s stock.
Insider Transactions at Dynavax Technologies
In related news, insider Justin Burgess sold 6,000 shares of the stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $10.00, for a total value of $60,000.00. Following the sale, the insider now directly owns 3,854 shares in the company, valued at approximately $38,540. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.31% of the stock is owned by insiders.
Dynavax Technologies Company Profile
(Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Stories
- Get a free copy of the StockNews.com research report on Dynavax Technologies (DVAX)
- Electric Vehicles Can Drive Alcoa Stock Higher
- Can Airbnb Still Thrive in a Recession?
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- What to Expect from the Markets in a Recession
- MarketBeat: Week in Review 8/1 – 8/5
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dynavax Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Dynavax Technologies wasn’t on the list.
While Dynavax Technologies currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Today, Kate’s guest is Rhys Williams, chief investment officer for the Opportunistic All Cap Equity, a long-short strategy at Spouting Rock Asset Management.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.
Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.